-
Study aim
-
Study of the synergistic effects of grape seed extract with deferasirox on oxidative stress, hemoglobin levels, blood coagulation, serum ferritin levels and inflammatory biomarkers in children with major thalassemia
-
Design
-
A randomized, blinded, controlled clinical trial of 60 patients, enrolled between August 2020 and March 2021, and followed for 2 months
-
Settings and conduct
-
A randomized, blinded controlled clinical trial of 60 children with thalassemia major who meets inclusion criteria without any of the exclusion criteria are enrolled in the study. The study is performed in hematology and oncology Specialty and sub-specialty shahid Baghaee 2 hospital. Patients are randomly stratified into 2 groups. The first group receives deferasirox 30 mg/Kg PO daily and the second group receives deferasirox 30 mg/Kg PO daily plus grape seed extract 100 mg PO daily. patients and major researcher are blinded via simulation of drug and placebo packages. Data is collected at the start of the study, after 2 weeks and 4 weeks of treatment.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Patients affected by major thalassemia; Iron chelators consumption for at least 2 years; A history of iron chelators steady dose for the last 3 months; Having serum ferritin level more than 1000 μg/L
Exclusion criteria: Change in iron chelator therapy during the study (6 months)
-
Intervention groups
-
Control group receives deferasirox 30mg /Kg daily PO.
Case group receives deferasirox 30 mg/Kg daily plus grape seed extract 100 mg daily PO.
-
Main outcome variables
-
Glutathione peroxidase, superoxide dismutase, malondialdehyde, Glutathione, Hemoglobin, red blood cell count, prothrombin time, partial thromboplastin time,international normalized ratio, Billirubin direct and indirect, aminotransferase enzymes, alkaline phosphatase, Ferritin level, catalase enzyme activity, tissue necrosis factor-α, serum Albumin